{"created":"2023-05-15T09:57:37.912148+00:00","id":1464,"links":{},"metadata":{"_buckets":{"deposit":"a48d95ab-a08b-4dc7-85a6-299c410dba8d"},"_deposit":{"created_by":5,"id":"1464","owner":"5","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"1464"},"status":"published"},"_oai":{"id":"oai:miyazaki-u.repo.nii.ac.jp:00001464","sets":["72","72:30"]},"author_link":["8016"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"359","bibliographicPageStart":"355","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"最新精神医学","bibliographic_titleLang":"ja"},{"bibliographic_title":"The Japanese journal of psychiatry","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"現在,本邦で使用可能な抗てんかん薬を用いても,てんかん発作を抑制できないいわゆる難治てんかん患者は,てんかん患者全体の20～30%存在すると報告されている｡一方,既存の抗てんかん薬には,副作用の発現により投与を中止しなければならない,あるいはその副作用に耐えながらの治療を継続せざるを得ないなど,安全性における問題点がある｡既存の抗てんかん薬では十分に発作をコントロールできない,いわゆる難治てんかんに対し有効で安全性に優れた薬剤への期待が高まっている中,欧米に遅れて日本でもガバペンチン（ガバペン）, トピラマート（トビナ）,ラモトリギン（ラミクタール）が上市された｡ここでは治験を終えて現在承認申請中であるレベチラセタムについて言及する｡","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"世論時報社","subitem_publisher_language":"ja"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN10582908","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"13424300","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"植田, 勇人","creatorNameLang":"ja"},{"creatorName":"ウエダ, ユウト","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-06-21"}],"displaytype":"detail","filename":"ueda200907.pdf","filesize":[{"value":"342.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ueda200907.pdf","url":"https://miyazaki-u.repo.nii.ac.jp/record/1464/files/ueda200907.pdf"},"version_id":"6670e2fb-f0db-44e0-a0a3-0df4abdcde47"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"epilepsy, levetiracetam, anti-epileptic drug, partial seizure","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"レベチラセタム","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"レベチラセタム","subitem_title_language":"ja"}]},"item_type_id":"10001","owner":"5","path":["72","30"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2009-09-04"},"publish_date":"2009-09-04","publish_status":"0","recid":"1464","relation_version_is_last":true,"title":["レベチラセタム"],"weko_creator_id":"5","weko_shared_id":2},"updated":"2024-01-30T04:20:58.522351+00:00"}